Table 2.
HIMRISS values from baseline to 52 weeks in the biological group and non-biological group.
| Group | Baseline | Treatment 52 weeks | Changed levels | Baseline vs. week 52 p-value | |
|---|---|---|---|---|---|
| BME of femoral headmean
(0–65) |
TNF-α group | 10.53 ± 6.78 | 7.74 ± 5.77 | 2.86 ± 0.38 | 0.000 |
| Control group | 9.74 ± 5.77 | 8.73 ± 5.06 | 0.74 ± 0.40 | 0.018 | |
| TNF vs. control p-value | 0.124 | 0.315 | 0.001 | ||
| BME of acetabularmean
(0–35) |
TNF-α group | 7.06 ± 3.68 | 5.51 ± 3.81 | 1.60 ± 0.23 | 0.000 |
| Control group | 6.27 ± 2.82 | 5.89 ± 2.45 | 0.33 ± 0.26 | 0.164 | |
| TNF vs. control p-value | 0.006 | 0.000 | 0.028 | ||
| Total BMEmean
(0–100) |
TNF-α group | 17.59 ± 9.36 | 13.26 ± 8.75 | 4.46 ± 0.52 | 0.000 |
| Control group | 16.05 ± 7.11 | 14.61 ± 2.44 | 1.06 ± 0.55 | 0.019 | |
| TNF vs. control p-value | 0.047 | 0.037 | 0.005 | ||
| Synovitis effusion scoremean
(0–30) |
TNF-α group | 8.90 ± 3.33 | 7.34 ± 2.97 | 1.53 ± 0.23 | 0.000 |
| Control group | 8.44 ± 2.19 | 7.71 ± 2.24 | 0.48 ± 0.23 | 0.011 | |
| TNF vs. control p-value | 0.002 | 0.088 | 0.000 | ||
| Total HIMRISSave
(0–130) |
TNF-α group | 26.49 ± 10.37 | 20.59 ± 9.41 | 5.99 ± 0.58 | 0.000 |
| Control group | 24.49 ± 8.07 | 22.33 ± 7.07 | 1.54 ± 0.66 | 0.039 | |
| TNF vs. control p-value | 0.073 | 0.079 | 0.011 | ||
| Total HIMRISSmax
(0–130) |
TNF-α group | 29.95 ± 11.70 | 23.03 ± 10.31 | 7.07 ± 0.66 | 0.000 |
| Control group | 27.31 ± 9.50 | 24.64 ± 8.38 | 1.91 ± 0.73 | 0.015 | |
| TNF vs. control p-value | 0.118 | 0.126 | 0.007 |
ave, the average score of two hips; max, the max score of two hips; changed levels, score at baseline minus score at week 52; HIMRISS, Hip Inflammation MRI Scoring System; BME, bone marrow edema.